At a glance
ClinicalIndex Comparison RecordPhase 3Unknown· 1,000 target
Drug / intervention
Epirubicin, CTX, Paclitaxel +1 moredrug
Likely dose
Epirubicin, CTX, Paclitaxel 90mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 3 Study of Regimens Comparison for Breast Cancers of Positive Lymph Nodes
In Brief
A Phase 3 clinical trial evaluating Epirubicin, CTX, Paclitaxel and Epirubicin, Paclitaxel for Breast Cancer. Targeting 1,000 participants across 1 site.
Detailed Summary
To compare the efficacy and safety of EC-T and ET regimen as adjuvant treatment of breast cancer patients with positive lymph nodes
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesChina
Collaborators--
Timeline
Phase 3UnknownOverdue
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2010
First PostedJun 2010
Primary CompletionMay 2018
Study CompletionMay 2020
TodayJul 2026
First PostedJun 2, 2010
Enrollment StartMay 1, 2010
Primary CompletionMay 1, 2018
Study CompletionMay 1, 2020
TodayJul 1, 2026
Enrollment to primary: 8 yearsPosted 16.1 years ago
Interventions
Epirubicin, CTX, Paclitaxeldrug
Epirubicin 90mg/m2 and CTX 600mg/m2 on day1 of each 21-day cycle, 4 cycles; followed by Paclitaxel 175mg/m2 on day1 of each 21-day cycle, 4 cycles.
Epirubicin, Paclitaxeldrug
Epirubicin 75mg/m2 on day1 and Paclitaxel 175mg/m2 on day2 of each 21-day cycle, 6 cycles.